Article Text

Download PDFPDF

442-H IL-21 on/off switch CAR-T enhance anti-tumor effects by epigenetic and transcriptional regulation
  1. Hyungseok Seo
  1. Seoul National University, Seoul, Republic of Korea

Abstract

Background The orchestration of T cell responses, particularly CD8+ T cells, through complex epigenetic and transcriptional mechanisms, plays a crucial role in boosting anti-tumor immunity.1–3 The interplay between TET enzymes as essential epigenetic modulators and BATF, a central transcription factor for T cell functionality, stands out as a key regulatory mechanism.4 5

Methods This study draws upon our previous findings, where we identified the effects of TET deficiency on BATF expression, and its pivotal role in countering T cell exhaustion through the inhibition of TOX and NR4A. Additionally, we found that TOX and NR4a repressed IL-21 secretion in CAR-T cells. Based on these insights, we developed a novel approach by pairing TET knockout (KO) with IL-21-mediated BATF upregulation, integrating an IL-21 on/off switch using a destabilization domain, thus enabling controlled IL-21 secretion via a small molecule. The resulting impact on tumor-infiltrating CD8+ T cell survival, expansion, effector functionality, and exhaustion was systematically assessed.

Results Our dual intervention significantly amplified the anti-tumor responses of CD8+ T cells. The data showcased a marked enhancement in the survival, expansion, and effector functionality of these cells within tumors, accompanied by a substantial reduction in exhaustion. These changes were reflected in the decreased expression of inhibitory receptors and exhaustion-linked transcription factors. Notably, our on/off switch system successfully controlled IL-21 secretion using a small molecule.

Conclusions This research pioneers a promising therapeutic strategy that melds both epigenetic and transcriptional manipulation, specifically through TET inhibition and IL-21-driven BATF overexpression, enhanced by TOX and NR4a downregulation. The integrated approach, including the innovative on/off switch for IL-21 secretion, has the potential to significantly amplify CD8+ T cell anti-tumor responses. This multifaceted strategy opens new paths for refining and augmenting the effectiveness of cancer immunotherapy.

Acknowledgements This work was supported by the New Faculty Startup Fund and Creative-Pioneering Researchers Program from Seoul National University, and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT)(No. RS-2023-00242443, RS-2023-00210035).

References

  1. Seo H, González-Avalos E, Zhang W, et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat Immunol 2021;22:983–995.

  2. Seo H, Chen J, Gonzalez-Avalos E, Samaniego-Castruita D, Das A. Wang YH, Lopez-Moyado IF, Georges RO, Zhang W, Onodera A, Wu C-J, Lu L-F, Hogan PG, Bhandoola A, Rao A. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc Natl Acad Sci USA. Jun 18 2019;116(25):12410–12415.

  3. Chen J, Lopez-Moyado IF, Seo H, Lio C-WJ, Hempleman LJ, Sekiya T, Yoshimura A, Scott-Browne JP, Rao A. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567:530–534.

  4. Jain N, Zhao Z, Feucht J, et al. TET2 guards against unchecked BATF3-induced CAR T cell expansion. Nature 2023;615:315–322.

  5. Fraietta JA, Nobles CL, Sammons MA, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 2018;558:307–312.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.